As of 2025-09-17, the EV/EBITDA ratio of Lineage Cell Therapeutics Inc (LCTX) is -9.44. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. LCTX's latest enterprise value is 272.96 mil USD. LCTX's TTM EBITDA according to its financial statements is -28.92 mil USD. Dividing these 2 quantities gives us the above LCTX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | - | - |
| Forward P/E multiples | - | - |
| Fair Price | - | - |
| Upside | - | - |
| Date | EV/EBITDA |
| 2025-09-16 | -9.44 |
| 2025-09-15 | -9.20 |
| 2025-09-12 | -9.12 |
| 2025-09-11 | -8.73 |
| 2025-09-10 | -8.10 |
| 2025-09-09 | -8.57 |
| 2025-09-08 | -8.33 |
| 2025-09-05 | -8.17 |
| 2025-09-04 | -8.02 |
| 2025-09-03 | -8.25 |
| 2025-09-02 | -8.17 |
| 2025-08-29 | -7.78 |
| 2025-08-28 | -8.10 |
| 2025-08-27 | -8.17 |
| 2025-08-26 | -8.41 |
| 2025-08-25 | -7.78 |
| 2025-08-22 | -8.02 |
| 2025-08-21 | -7.78 |
| 2025-08-20 | -7.94 |
| 2025-08-19 | -8.33 |
| 2025-08-18 | -8.65 |
| 2025-08-15 | -8.02 |
| 2025-08-14 | -6.60 |
| 2025-08-13 | -6.67 |
| 2025-08-12 | -6.52 |
| 2025-08-11 | -6.52 |
| 2025-08-08 | -6.31 |
| 2025-08-07 | -6.05 |
| 2025-08-06 | -6.36 |
| 2025-08-05 | -6.12 |
| 2025-08-04 | -6.20 |
| 2025-08-01 | -6.32 |
| 2025-07-31 | -6.60 |
| 2025-07-30 | -6.67 |
| 2025-07-29 | -6.99 |
| 2025-07-28 | -7.78 |
| 2025-07-25 | -7.46 |
| 2025-07-24 | -7.62 |
| 2025-07-23 | -7.07 |
| 2025-07-22 | -6.04 |
| 2025-07-21 | -6.00 |
| 2025-07-18 | -6.13 |
| 2025-07-17 | -6.36 |
| 2025-07-16 | -6.60 |
| 2025-07-15 | -6.44 |
| 2025-07-14 | -6.99 |
| 2025-07-11 | -6.67 |
| 2025-07-10 | -6.60 |
| 2025-07-09 | -6.91 |
| 2025-07-08 | -6.32 |